Well, enGene is a unique company with unique technology at actually a really unique time, right? So our technology is called the DDX pl ...

Detailed price information for Engene Holdings Inc (ENGN-Q) from The Globe and Mail including charting and trades.

LEGEND pivotal cohort update planned for a spring 2026 medical conference12-month complete response data from LEGEND pivotal cohort expected in 2H 2026Biologics License Application (BLA) submission ...

Did you know that Florida is the only state in the nation where multiple public university police departments are partnering with U.S. Immigration and Customs Enforcement (ICE) to assist in ...

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it has entered into an ...

NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today ...

Shares of Beam Therapeutics BEAM were up 22.3% on Monday after the company outlined strategic priorities and some expected milestones related to its gene therapy pipeline candidates for 2026. Beam ...

New York-based clinical-stage cancer and rare diseases drug developer Protara Therapeutics (Nasdaq: TARA) today announced that the US Food and Drug Administration (FDA) has granted both Breakthrough ...

As of October 31, 2025, cash, cash equivalents and marketable securities were $202.3 million. An additional $140.1 million in net proceeds was raised during a public offering in November. The Company ...

Completed enrollment in LEGEND’s pivotal cohort with 125 patients in high-risk, BCG-unresponsive NMIBC with carcinoma in situ Reported preliminary 6-month complete response rate (62%) in pivotal ...